Yesterday, the President & CEO of Eyegate (EYEG), Stephen From, sold shares of EYEG for $29.72K.
In addition to Stephen From, 4 other EYEG executives reported Sell trades in the last month. This is From’s first Sell trade following 3 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Eyegate’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $2.69 million and quarterly net profit of $870.8K. In comparison, last year the company earned revenue of $242K and had a GAAP net loss of $2.78 million. Currently, Eyegate has an average volume of 708.7K.
Stephen From’s trades have generated a -36.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
